Erik Tillman
Company: Akero Therapeutics
Job title: Director, Translational Biology and Pharmacology
Seminars:
9:30 am Leveraging Noninvasive Markers of Fibrosis Alongside Serial-Biopsy Clinical Studies of Efruxifermin to Elucidate Breadth of Response Across Advanced Fibrosis & Cirrhosis Due to MASH 9:30 am
Characterization of disease progression in untreated patients through longitudinal assessments in long-term studies Rapid and sustained effects of efruxifermin on fibrotic pathways to arrest progression and reverse fibrosis in MASH patients with advanced fibrosis and compensated cirrhosis Corroboration of improved liver health and underlying disease drivers as assessed by multiple measures of liver injury, fibrosis,…Read more
day: Conference Day 2